On January 15, 2021, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Enhertu (fam-trastuzumab deruxtecan-nxki). This approval, identified as supplemental Biologics License Application (sBLA) 761139 S-11, specifically addressed the efficacy of the drug and was granted to the sponsor, Daiichi Sankyo.
Background
Enhertu (fam-trastuzumab deruxtecan-nxki) is a therapeutic agent developed by Daiichi Sankyo. Supplemental applications to the FDA typically seek to update a drug's label, often by adding new indications, patient populations, dosing regimens, or by modifying existing information based on new clinical data. This particular supplemental approval focused on the drug's efficacy profile, suggesting new evidence supporting its therapeutic benefits and potentially expanding its approved uses.
What this means
The FDA's approval of this supplemental application for Enhertu signifies that new clinical evidence has been reviewed and accepted, supporting an expansion or refinement of the drug's approved uses. As this approval specifically pertains to efficacy, it indicates that Enhertu has demonstrated additional therapeutic benefits or has shown efficacy in a previously unapproved context. This development provides clinicians with updated information, potentially allowing them to consider Enhertu for a broader range of patients or under revised treatment protocols, enhancing its utility in patient care. The specifics of the label update would detail the precise changes to the drug's approved indications or usage.
Source
The information regarding this supplemental approval for Enhertu was sourced from the official U.S. Food and Drug Administration (FDA) website. The approval for Biologics License Application (BLA) 761139 S-11, concerning efficacy, was publicly recorded on January 15, 2021, on the accessdata.fda.gov domain, providing official documentation of this regulatory action.